New Trial Alert: LoTam Trial | Early-Stage Breast Cancer

February 6, 2025

Dean Shumway, MD, of Mayo Clinic, leads this phase III trial that compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the

• Read more

New Trial Alert: STRIKE Trial | Renal Cell Cancer

February 5, 2025

Alliance A032201 - Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE

Bradley McGregor, MD, of Dana-Farber Cancer Institute, leads this phase III trial that compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal a

• Read more

Spotlight on Alliance Trials at 2025 ASCO GI Symposium

January 28, 2025

• Read more